Brief: Argent BioPharma Posts HY Net Loss Attributable A$12.2 Million
28/02/2025 08:19
Feb 28 (Reuters) - Argent BioPharma Ltd RGT.AX: HY NET LOSS ATTRIBUTABLE A$12.2 MILLION Source text: ID:nASX2LZQkC Further company coverage: RGT.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Argent BioPharma
See all newsBrief: Argent Biopharma Enters Long Term Aquiol Licensing And Supply Agreement
Brief: Argent Biopharma Secures A$11M Financing Facility To Complete Strategic Acquisition
Brief: Argent Is Growing Through M&A Projected Merged Company Value Of $100M In Ac8 Asset Acquisition
Australia's Argent BioPharma set for best day in a year on AusCann deal
Brief: Argent Biopharma To Acquire Core Operating Assets And IP Portfolio Of Auscann Group